Neurost provides customizable tauopathy modeling and anti-tau drug evaluation services for mechanistic studies, candidate prioritization, and preclinical screening in Alzheimer's disease and related tauopathies. Support can encompass model and study design, tau pathology induction or genetic modeling, compound treatment, imaging and biochemical readouts, data analysis, and scientific collaboration, with the final model configuration and endpoints defined for each research question.
Build a focused experimental package around the tau species, disease context, therapeutic modality, and decision criteria that matter to your program.
Select genetic, seeded, induced, or patient-derived approaches according to the target tau isoform, mutation, cell type, maturation state, and phenotype of interest.
Combine orthogonal biochemical and imaging endpoints to examine tau abundance, phosphorylation, conformation, aggregation, localization, neurite integrity, and cell health.
Evaluate small molecules, antibodies, oligonucleotide-based approaches, degraders, or other research candidates using project-appropriate concentration ranges, controls, and exposure schedules.
Translate assay outputs into a structured comparison of tau-modifying activity, cellular tolerance, phenotype rescue, and next-study priorities.
Tau is a microtubule-associated protein expressed as multiple isoforms in the adult human brain. In tauopathies, altered splicing, post-translational modification, conformational change, mislocalization, aggregation, and cell-to-cell propagation can contribute to distinct pathological phenotypes.
Because Alzheimer's disease, frontotemporal dementia with tau pathology, progressive supranuclear palsy, and corticobasal degeneration do not share one uniform tau state, model selection should begin with the intended mechanism and translational question rather than a single generic aggregation assay.
For broader disease-model development, explore Neurost's custom CNS disease modeling services.
The final strategy is selected after feasibility review; the options below describe model directions that can be considered, not a fixed one-size-fits-all package.
Use controlled tau expression, isoform selection, reporter systems, or selected MAPT variants to generate measurable pathology with defined experimental controls.
Introduce human neuronal context through iPSC-derived cells, including isogenic or disease-associated backgrounds where scientifically justified and available for the project.
Add neuron-glia interactions or 3D organization when cellular crosstalk, pathology propagation, or a broader degenerative phenotype is central to the study.
Review related Alzheimer's disease cell models and iPSC-derived neural models.
Measure total or soluble/insoluble tau fractions, selected phospho-epitopes, conformational states, or aggregate-associated signals.
Compare uptake, intracellular seeding, inclusion formation, or transfer-associated readouts using appropriate negative and positive controls.
Pair tau endpoints with viability, neurite morphology, stress-response, synaptic, or functional measures selected for the model.
Interpret tau modulation alongside cell count, membrane integrity, metabolic health, or other tolerance measurements.
Immunofluorescence, confocal analysis, high-content morphology, colocalization, and inclusion quantification.
Immunoblotting, immunoassays, solubility fractionation, or other fit-for-purpose protein measurements.
Reporter-based, seed-responsive, or aggregate-selective assay formats where compatible with the study.
Viability, neurite architecture, cellular stress, localization, and selected pathway markers.
Projects requiring automated image-based multiparametric analysis can be aligned with Neurost's high-content screening service.
Clarify mechanism, disease context, modality, sample constraints, and decision criteria.
Select model, controls, treatment matrix, endpoints, replicates, and analysis plan.
Confirm assay window, sample handling, readout suitability, and acceptance criteria.
Run the approved study with scheduled quality-control review and documented deviations.
Deliver organized data, methods, analysis, interpretation, and a scientific review discussion.
Use tauopathy models to connect a therapeutic hypothesis to measurable pathology and cellular outcomes across discovery stages.
Test whether genetic or pharmacological perturbation modifies a defined tau phenotype.
Compare candidate activity across concentration, endpoint, and cellular-tolerance dimensions.
Distinguish effects on tau production, modification, aggregation, clearance, or propagation.
Examine responses across selected mutations, isoform contexts, cell types, or disease-associated backgrounds.
Relate treatment response to project-relevant molecular or imaging markers.
Confirm a screening signal with an independent method or a more biologically complex model.
Deliverables are agreed in the study plan and can include model and assay documentation, quality-control summaries, raw and processed data, image sets, statistical outputs, and a report describing methods, results, limitations, and interpretation.
Fill out the form below, and our expert team will contact you to design your custom project and accelerate breakthrough innovations.
